Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Hepatocellular 121Carcinoma, Renal Cell 60Neoplasms 43Liver Neoplasms 42Neoplasm Metastasis 23Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Melanoma 18Kidney Neoplasms 16Breast Neoplasms 16Brain Neoplasms 13Pancreatic Neoplasms 12Sarcoma 11Prostatic Neoplasms 10Glioblastoma 10Lung Neoplasms 9Thyroid Neoplasms 8Recurrence 8Rectal Neoplasms 8Colorectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Colonic Neoplasms 7Stomach Neoplasms 6Ovarian Neoplasms 6Multiple Myeloma 6Leukemia 6Gliosarcoma 6Carcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Urinary Bladder Neoplasms 4

Interventions

Cisplatin 150Radiotherapy 121Cetuximab 96Docetaxel 60Fluorouracil 56Paclitaxel 45Radiotherapy, Intensity-Modulated 41Carboplatin 40pembrolizumab 34Surveys and Questionnaires 22Erlotinib Hydrochloride 19Nivolumab 18Immunohistochemistry 16Gefitinib 16Drug Therapy 16Gemcitabine 14Pemetrexed 13Gene Expression Profiling 13durvalumab 12Chemotherapy, Adjuvant 12Radiation 11Filgrastim 11Bevacizumab 11Surgical Procedures, Operative 10Polymerase Chain Reaction 10Amifostine 10Celecoxib 9Capecitabine 9Standard of Care 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Head and Neck Neoplasms × Sorafenib × Clear all
NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
16 enrolled
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00199160 2015-05-20

Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Jules Bordet Institute

Phase 2 Completed
60 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡